Research shows amino acid restriction slows prostate cancer growth and spread in mice — Evidence Review
Published in Nature Metabolism, by researchers from Weill Cornell Medicine
Researched by
— the AI search engine for science
Table of Contents
A new study in mice suggests that restricting the amino acids isoleucine and valine may slow the growth and spread of prostate cancer by disrupting a metabolic pathway linked to cholesterol production. Related studies generally support the connection between branched-chain amino acids and prostate cancer risk, indicating the findings align with emerging research on amino acid metabolism and tumor progression from Weill Cornell Medicine.
- Multiple studies have found that elevated levels of branched-chain amino acids, including isoleucine and valine, are associated with increased prostate cancer risk, reinforcing the new study’s focus on these nutrients as potential drivers of disease progression 1 2.
- Experimental research demonstrates that targeting amino acid transporters or restricting specific amino acids can impair tumor growth in various models, supporting the therapeutic potential of manipulating amino acid metabolism in cancer 3 4 5 6.
- Literature reviews emphasize that alterations in amino acid metabolism are increasingly recognized as key features of cancer biology and may offer novel targets for therapy, especially in tumors reliant on specific metabolic pathways 2 5.
Study Overview and Key Findings
Prostate cancer often develops resistance to hormone therapies that block androgen signaling, leading to more aggressive disease. This study investigated a metabolic adaptation mechanism involving the amino acids isoleucine and valine, which, when metabolized, generate a compound (propionyl-CoA) that promotes ongoing cholesterol synthesis even in hormone-deprived conditions. The research highlights a previously unrecognized link between dietary nutrients, cholesterol metabolism, and tumor adaptation to therapy—suggesting that dietary or pharmacological interventions could influence prostate cancer outcomes.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Weill Cornell Medicine |
| Journal Name | Nature Metabolism |
| Authors | Zhongchi Li, Shuchen Liu, Wenbing Jin, Leyi Xiao, Olivia Kester, Nayah Bullen, Xuanrong Chen, Un In Chan, Jude Owiredu, Zhucui Li, Rabia Khan, Jennifer Endress, Moniquetta Shafer, Vivien Low, Nikolaos Koundouros, Sungyun Cho, Christopher Barbieri, Chun-Jun Guo, John Blenis |
| Population | Mice |
| Methods | Animal Study |
| Outcome | Prostate tumor growth and spread of cancer cells |
| Results | Restricting isoleucine and valine slowed tumor growth and spread. |
Literature Review: Related Studies
To place the recent findings in context, we searched the Consensus database of over 200 million research papers. The following search queries were used to identify relevant studies:
- isoleucine valine prostate cancer effects
- amino acids tumor growth inhibition
- prostate cancer mouse model studies
Summary Table of Topics and Key Findings
| Topic | Key Findings |
|---|---|
| How do branched-chain amino acids (BCAAs) relate to prostate cancer? | - Elevated circulating levels of BCAAs, including isoleucine and valine, are associated with increased prostate cancer risk in population studies 1. - Altered BCAA metabolism is linked to cancer progression and may serve as a therapeutic target 2 5. |
| Can manipulating amino acid metabolism or transport inhibit tumor growth? | - Restricting certain amino acids, such as serine or BCAAs, slows tumor growth in preclinical models 3 4 5 6. - Inhibitors of amino acid transporters (e.g., ASCT2, LAT1) reduce cancer cell proliferation and tumor burden 3 6. |
| What is the role of mouse models in understanding prostate cancer metabolism? | - Genetically defined and xenograft mouse models accurately mimic human prostate cancer development and metabolic adaptations 7 8 9 10 11. - Mouse models enable evaluation of dietary and metabolic interventions, as well as therapy resistance mechanisms 8 9 11. |
How do branched-chain amino acids (BCAAs) relate to prostate cancer?
Several studies indicate a positive association between high circulating levels of BCAAs—including isoleucine and valine—and increased prostate cancer risk, aligning with the new study's focus on these amino acids as contributors to tumor progression. Reviews highlight that amino acid metabolism, particularly involving BCAAs, is frequently altered in cancer and may facilitate disease advancement or serve as a potential therapeutic target. The evidence supports the new study's rationale for investigating dietary manipulation as a possible intervention for prostate cancer 1 2 5.
- Mendelian randomization studies show elevated BCAAs (including isoleucine and valine) are linked to higher prostate cancer risk, but not to kidney or bladder cancer 1.
- Literature reviews emphasize that BCAA metabolism can serve as a biomarker and therapeutic target in cancer 2 5.
- Targeting BCAA metabolic pathways could disrupt tumor growth and progression 2 5.
- The new mouse study’s findings are consistent with human epidemiological and mechanistic research on BCAAs in prostate cancer 1 2 5.
Can manipulating amino acid metabolism or transport inhibit tumor growth?
Research demonstrates that restricting specific amino acids or inhibiting their uptake by cancer cells can impede tumor growth, supporting strategies that target amino acid metabolism in cancer therapy. Inhibitors of amino acid transporters, such as ASCT2 and LAT1, as well as dietary restriction of amino acids like serine or BCAAs, have shown tumor-suppressive effects in preclinical models. These findings reinforce the potential of dietary or pharmacological interventions targeting amino acid metabolism, as proposed in the new study 3 4 5 6.
- Inhibitors of amino acid transporters (ASCT2, LAT1) reduce uptake of key amino acids, suppressing tumor cell proliferation and growth in vitro and in animal models 3 6.
- Dietary restriction of amino acids, including serine and BCAAs, slows tumor growth and may induce accumulation of toxic metabolites that stress tumor cells 4 5.
- Targeting amino acid metabolism is emerging as a viable strategy in cancer therapy, with evidence from multiple tumor types 2 5.
- The new study’s approach of restricting isoleucine and valine fits within a broader trend of targeting nutrient dependencies in cancer 3 4 5 6.
What is the role of mouse models in understanding prostate cancer metabolism?
Mouse models have become essential for studying prostate cancer development, metabolic adaptations, and treatment responses. Genetically engineered and xenograft models closely mimic aspects of human disease, enabling detailed investigation of dietary, metabolic, and genetic interventions. The new study’s use of mouse models to assess the effects of amino acid restriction is consistent with best practices in the field and highlights the relevance of animal studies for preclinical cancer research 7 8 9 10 11.
- Genetically defined mouse models replicate key features of human prostate cancer, including metabolic reprogramming and therapy resistance 7 9 11.
- Animal models allow controlled testing of dietary and metabolic interventions not feasible in humans, offering insights into mechanisms and therapeutic potential 8 9 11.
- Mouse models have advanced understanding of prostate cancer biology, including the role of nutrient availability and metabolic pathways 10 11.
- The new study’s findings in mice provide a foundation for potential clinical translation, pending further research 7 8 9 10 11.
Future Research Questions
Further research is essential to determine whether the findings from mouse models translate to humans, to clarify the safety and feasibility of dietary amino acid restriction, and to explore the broader role of amino acid metabolism in therapy resistance and cancer progression. Addressing these questions will help define the therapeutic potential and limitations of targeting amino acid pathways in prostate cancer and other malignancies.
| Research Question | Relevance |
|---|---|
| Does dietary restriction of isoleucine and valine improve prostate cancer outcomes in humans? | Mouse studies support efficacy, but human data are needed to assess safety, effectiveness, and practicality of such dietary interventions 1 2 5. |
| What are the long-term effects of amino acid restriction on overall health? | Understanding potential side effects or risks is crucial before clinical application, as amino acids are essential nutrients for normal physiology 2 5. |
| Can pharmacological inhibition of isoleucine and valine metabolism prevent therapy resistance in prostate cancer? | The study suggests targeting metabolic enzymes may limit resistance to androgen receptor therapies, but this approach requires validation in clinical models 5. |
| Does altered BCAA metabolism predict response to cholesterol-lowering drugs in prostate cancer? | Identifying biomarkers that predict benefit from statins or similar agents could guide personalized therapy decisions 1. |
| Is the propionyl-CoA signaling pathway implicated in other cancers or metabolic diseases? | Exploring the pathway’s role in different contexts may uncover broader implications for cancer biology and treatment strategies 2 5. |